Innovative delivery of DNA and RNA vaccines for melanoma treatment
Official title: Next Generation Gene-Gun Delivered DNA and RNA Immunotherapeutic Vaccines for Melanoma.
Funded at Orlance, INC. · NIH-10932954 · Data updated 2026-11-12
This study is testing a new way to deliver DNA and RNA vaccines directly into the skin to help your body fight melanoma, using a special device that makes it easy and painless, while also personalizing the treatment based on your unique tumor.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Orlance, INC. NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 21, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $200,000 |
| NIH project number | 5R43CA281585-02 |
| Project ID | NIH-10932954 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with melanoma who may benefit from personalized cancer vaccines.
✕Less likely to help
Patients with non-melanoma skin cancers or those who do not have identifiable neoantigens may not benefit from this research.
What this research studies
This research focuses on developing a next-generation Gene Gun that delivers DNA and RNA vaccines directly into skin cells to stimulate a strong immune response against melanoma. By sequencing tumors from individual patients, the study aims to identify personalized neoantigens that can be targeted with these vaccines. The Gene Gun technology allows for painless delivery of low doses of vaccines, which could lead to effective localized and systemic immune responses. This approach seeks to overcome limitations of current vaccine delivery methods, such as high doses and storage challenges.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for melanoma patients through personalized immunotherapy.
How similar studies have gone: Previous research has shown promise in using similar gene delivery technologies for cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
-
Orlance, INC.
Seattle, United States Active
Researchers
- Principal investigator: Frizzell, Hannah — Orlance, INC.
- Study coordinator: Frizzell, Hannah
Related research
Other NIH-funded projects on the same topics.
-
Melanoma vaccine built from tiny spherical nucleic acids
A new kind of cancer vaccine using tiny spherical nucleic acids to help the immune system fight advanced melanoma.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
SIRT6 and melanoma growth and spread
Researchers are seeing if blocking a protein called SIRT6 can help stop melanoma from growing and spreading in people with melanoma.
-
How tumor cell stress and nearby support cells help melanoma spread
This project looks at whether blocking a tumor cell stress response and changing how nearby support cells behave might keep melanoma cells from surviving, spreading, and resisting treatment.
-
PLK4 as a potential drug target in melanoma
Researchers are exploring whether blocking PLK4 could be a new way to treat melanoma and how PLK4 works with other melanoma-driving pathways.
-
A new lentivector to deliver multiple TCRs for melanoma cell therapy
A new gene-delivery approach aims to boost T cell receptors inside patients’ own cells to treat advanced melanoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.